| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Editorial; Comment; Journal Article
- Language: English
- [Hepatology] 2024 Jul 01; Vol. 80 (1), pp. 8-10. <i>Date of Electronic Publication: </i>2024 Feb 16.
- MeSH Terms: PPAR alpha* / agonists ; PPAR delta* / genetics ; Humans ; Animals ; Mice ; Fatty Liver
- References: Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: Understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2023;20:26–36. ; Kremer AE, Martens JJWW, Kulik W, Ruëff F, Kuiper EMM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008–1018. ; Kuiper EMM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:1334–40. ; Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171–81. ; de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: A double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160:734–43 e6. ; Shen N, Pan J, Miao H, Zhang H, Xing L, Yu X. Fibrates for the treatment of pruritus in primary biliary cholangitis: A systematic review and meta-analysis. Ann Palliat Med. 2021;10:7697–705. ; Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo- controlled study. Hepatology. 2023;78:397–415. ; Kremer AE, Mayo MJ, Hirschfield GM, et al. Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2023. doi: 10.1097/HEP.0000000000000728. Epub ahead of print. PMID: 38117036. (PMID: 10.1097/HEP.0000000000000728) ; Xu J, Wang Y, Khoshdeli M, Peach M, Chuang JC, Lin J, et al. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology. 2023;77:20–32. ; Tang L, Gao J, Cao X, Chen L, Wang H, Ding H. TRPV1 mediates itch-associated scratching and skin barrier dysfunction in DNFB-induced atopic dermatitis mice. Exp Dermatol. 2022;31:398–405.
- Substance Nomenclature: 0 (PPAR alpha) ; 0 (PPAR delta)
- Entry Date(s): Date Created: 20240219 Date Completed: 20240619 Latest Revision: 20240619
- Update Code: 20240619
|
